Skip to main content
Erschienen in: Tumor Biology 6/2016

23.12.2015 | Original Article

TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas

Erschienen in: Tumor Biology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Squamous cell carcinoma (SCC) of the uterine cervix and oral cavity are most common cancers in India. Telomerase reverse transcriptase (TERT) overexpression is one of the hallmarks for cancer, and activation through promoter mutation C228T and C250T has been reported in variety of tumors and often shown to be associated with aggressive tumors. In the present study, we analyzed these two hot spot mutations in 181 primary tumors of the uterine cervix and oral cavity by direct DNA sequencing and correlated with patient’s clinicopathological characteristics. We found relatively high frequency of TERT hot spot mutations in both cervical [21.4 % (30/140)] and oral [31.7 % (13/41)] squamous cell carcinomas. In cervical cancer, TERT promoter mutations were more prevalent (25 %) in human papilloma virus (HPV)-negative cases compared to HPV-positive cases (20.6 %), and both TERT promoter mutation and HPV infection were more commonly observed in advanced stage tumors (77 %). Similarly, the poor and moderately differentiated tumors of the uterine cervix had both the TERT hot spot mutations and HPV (16 and 18) at higher frequency (95.7 %). Interestingly, we observed eight homozygous mutations (six 228TT and two 250TT) only in cervical tumors, and all of them were found to be positive for high-risk HPV. To the best of our knowledge, this is the first study from India reporting high prevalence of TERT promoter mutations in primary tumors of the uterine cervix and oral cavity. Our results suggest that TERT reactivation through promoter mutation either alone or in association with the HPV oncogenes (E6 and E7) could play an important role in the carcinogenesis of cervical and oral cancers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11. Lyon: International Agency for Research on Cancer; 2012. Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11. Lyon: International Agency for Research on Cancer; 2012.
2.
Zurück zum Zitat Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11. International Agency for Research on Cancer 1.0. 2013. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11. International Agency for Research on Cancer 1.0. 2013.
3.
Zurück zum Zitat Bosch FX, de Sanjose S Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;3–13. Bosch FX, de Sanjose S Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;3–13.
4.
Zurück zum Zitat Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, et al. Cancer mortality in India: a nationally representative survey. Lancet. 2012;379:1807–16.CrossRefPubMed Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, et al. Cancer mortality in India: a nationally representative survey. Lancet. 2012;379:1807–16.CrossRefPubMed
5.
Zurück zum Zitat Byakodi R, Byakodi S, Hiremath S, Byakodi J, Adaki S, et al. Oral cancer in India: an epidemiologic and clinical review. J Community Health. 2012;37:316–9.CrossRefPubMed Byakodi R, Byakodi S, Hiremath S, Byakodi J, Adaki S, et al. Oral cancer in India: an epidemiologic and clinical review. J Community Health. 2012;37:316–9.CrossRefPubMed
6.
Zurück zum Zitat IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans (2003). v. 85. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans (2003). v. 85.
7.
Zurück zum Zitat Gupta PC, Ray CS, Sinha DN, Singh PK. Smokeless tobacco: a major public health problem in the SEA region: a review. Indian J Public Health. 2011;55:199–209.CrossRefPubMed Gupta PC, Ray CS, Sinha DN, Singh PK. Smokeless tobacco: a major public health problem in the SEA region: a review. Indian J Public Health. 2011;55:199–209.CrossRefPubMed
8.
Zurück zum Zitat Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996;18:173–9.CrossRefPubMed Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996;18:173–9.CrossRefPubMed
9.
Zurück zum Zitat Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.CrossRefPubMed Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.CrossRefPubMed
10.
Zurück zum Zitat Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787–91.CrossRefPubMed Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787–91.CrossRefPubMed
11.
Zurück zum Zitat Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959–61.CrossRefPubMed Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959–61.CrossRefPubMed
12.
13.
Zurück zum Zitat Zhang Z, Yang X, Meng L, Liu F, Shen C, et al. Enhanced amplification of GC-rich DNA with two organic reagents. Biotechniques. 2009;47:775–9.CrossRefPubMed Zhang Z, Yang X, Meng L, Liu F, Shen C, et al. Enhanced amplification of GC-rich DNA with two organic reagents. Biotechniques. 2009;47:775–9.CrossRefPubMed
14.
Zurück zum Zitat Vogelstein B, Kinzler KW. The path to cancer—three strikes and you’re out. N Engl J Med. 2015;373:1895–8.CrossRefPubMed Vogelstein B, Kinzler KW. The path to cancer—three strikes and you’re out. N Engl J Med. 2015;373:1895–8.CrossRefPubMed
15.
16.
Zurück zum Zitat Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8:137–42.CrossRefPubMed Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8:137–42.CrossRefPubMed
17.
Zurück zum Zitat Liu X, Bishop J, Shan Y, Pai S, Liu D, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603–10.CrossRefPubMedPubMedCentral Liu X, Bishop J, Shan Y, Pai S, Liu D, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603–10.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110:17426–31.CrossRefPubMedPubMedCentral Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110:17426–31.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110:6021–6.CrossRefPubMedPubMedCentral Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110:6021–6.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Griewank KG, Murali R, Schilling B, Schimming T, Moller I, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One. 2013;8:e80354.CrossRefPubMedPubMedCentral Griewank KG, Murali R, Schilling B, Schimming T, Moller I, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One. 2013;8:e80354.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98:E1562–6.CrossRefPubMedPubMedCentral Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98:E1562–6.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, et al. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12:1637–8.CrossRefPubMedPubMedCentral Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, et al. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12:1637–8.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218.CrossRefPubMedPubMedCentral Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Vinagre J, Almeida A, Populo H, Batista R, Lyra J, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.CrossRefPubMed Vinagre J, Almeida A, Populo H, Batista R, Lyra J, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.CrossRefPubMed
25.
Zurück zum Zitat Cheng KA, Kurtis B, Babayeva S, Zhuge J, Tantchou I, et al. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. Ann Diagn Pathol. 2015;19:146–8.CrossRefPubMed Cheng KA, Kurtis B, Babayeva S, Zhuge J, Tantchou I, et al. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. Ann Diagn Pathol. 2015;19:146–8.CrossRefPubMed
26.
Zurück zum Zitat Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol. 2014;232:473–81.CrossRefPubMedPubMedCentral Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol. 2014;232:473–81.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014;27:516–23.CrossRefPubMed Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014;27:516–23.CrossRefPubMed
28.
Zurück zum Zitat Mitra AB, Murty VV, Singh V, Li RG, Pratap M, et al. Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J Natl Cancer Inst. 1995;87:742–5.CrossRefPubMed Mitra AB, Murty VV, Singh V, Li RG, Pratap M, et al. Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J Natl Cancer Inst. 1995;87:742–5.CrossRefPubMed
29.
Zurück zum Zitat Mitra AB, Murty VV, Li RG, Pratap M, et al. Allelotype analysis of cervical carcinoma. Cancer Res. 1994;54:4481–7.PubMed Mitra AB, Murty VV, Li RG, Pratap M, et al. Allelotype analysis of cervical carcinoma. Cancer Res. 1994;54:4481–7.PubMed
30.
Zurück zum Zitat Atkin NB. Significance of chromosome 5 and 17 changes in the development of carcinoma of the cervix uteri. Cytogenet Cell Genet. 2000;91:44–6.CrossRefPubMed Atkin NB. Significance of chromosome 5 and 17 changes in the development of carcinoma of the cervix uteri. Cytogenet Cell Genet. 2000;91:44–6.CrossRefPubMed
31.
Zurück zum Zitat Gewin L, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004;18:2269–82.CrossRefPubMedPubMedCentral Gewin L, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004;18:2269–82.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 1998;396:84–8.CrossRefPubMed Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 1998;396:84–8.CrossRefPubMed
33.
Zurück zum Zitat Liu X, Dakic A, Chen R, Disbrow GL, Zhang Y, et al. Cell-restricted immortalization by human papillomavirus correlates with telomerase activation and engagement of the hTERT promoter by Myc. J Virol. 2008;82:11568–76.CrossRefPubMedPubMedCentral Liu X, Dakic A, Chen R, Disbrow GL, Zhang Y, et al. Cell-restricted immortalization by human papillomavirus correlates with telomerase activation and engagement of the hTERT promoter by Myc. J Virol. 2008;82:11568–76.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Liu X, Disbrow GL, Yuan H, Tomaic V, Schlegel R. Myc and human papillomavirus type 16 E7 genes cooperate to immortalize human keratinocytes. J Virol. 2007;81:12689–95.CrossRefPubMedPubMedCentral Liu X, Disbrow GL, Yuan H, Tomaic V, Schlegel R. Myc and human papillomavirus type 16 E7 genes cooperate to immortalize human keratinocytes. J Virol. 2007;81:12689–95.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology. 2008;375:611–23.CrossRefPubMedPubMedCentral Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology. 2008;375:611–23.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Liu X, Yuan H, Fu B, Disbrow GL, Apolinario T, et al. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem. 2005;280:10807–16.CrossRefPubMed Liu X, Yuan H, Fu B, Disbrow GL, Apolinario T, et al. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem. 2005;280:10807–16.CrossRefPubMed
38.
Zurück zum Zitat Oh ST, Kyo S, Laimins LA. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol. 2001;75:5559–66.CrossRefPubMedPubMedCentral Oh ST, Kyo S, Laimins LA. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol. 2001;75:5559–66.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology. 2009;384:324–34.CrossRefPubMed Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology. 2009;384:324–34.CrossRefPubMed
40.
Metadaten
Titel
TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas
Publikationsdatum
23.12.2015
Erschienen in
Tumor Biology / Ausgabe 6/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4694-2

Weitere Artikel der Ausgabe 6/2016

Tumor Biology 6/2016 Zur Ausgabe

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.